HealthLynked Narrows Losses Amidst Revenue Decline, Cash Dries Up

TL;DR

**HLYK is bleeding cash and shrinking, the reverse split is a red flag – stay away.**

AI Summary

HealthLynked Corp. (HLYK) reported a significant net loss of $851,800 for the three months ended September 30, 2025, a substantial improvement from the $1,973,119 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $2,603,777, down from $4,901,273 in 2024. Total revenue decreased to $388,545 for the three months ended September 30, 2025, from $590,124 in 2024, and to $1,755,113 for the nine months, from $2,389,434 in 2024. This decline was primarily driven by a drop in patient service revenue, which fell from $522,795 to $380,780 in the three-month period. Operating expenses and costs saw a substantial reduction, decreasing from $2,261,471 to $918,131 for the three months, largely due to lower practice salaries and benefits and the absence of a $716,000 impairment loss recorded in 2024. The company's cash position significantly deteriorated, with cash decreasing from $76,241 at December 31, 2024, to $10,911 at September 30, 2025. Total liabilities increased from $5,352,198 to $7,197,972 over the same period, driven by a rise in notes payable to related parties. A 1-for-100 reverse stock split was effected on September 4, 2025, reducing outstanding common shares from 284,750,832 to 2,847,873.

Why It Matters

HealthLynked's continued net losses and dwindling cash reserves, now at just $10,911, signal severe liquidity challenges for investors. The 1-for-100 reverse stock split, while reducing the share count, often indicates a company struggling to maintain its stock price and could lead to further dilution or delisting concerns. For employees and customers, the declining revenue across all divisions, particularly patient services, suggests potential operational instability and reduced service offerings. In a competitive healthcare technology and services market, HLYK's inability to grow revenue while still incurring significant losses puts it at a disadvantage against more financially robust competitors, raising questions about its long-term viability and ability to innovate.

Risk Assessment

Risk Level: high — The company's cash balance plummeted from $76,241 to $10,911, indicating severe liquidity issues. Total liabilities surged from $5,352,198 to $7,197,972, primarily due to a significant increase in notes payable to related parties from $3,212,521 to $5,216,072, highlighting a reliance on debt financing.

Analyst Insight

Investors should avoid HLYK given its critical cash shortage, increasing debt, and declining revenue across all segments. The reverse stock split and continued net losses suggest fundamental business challenges that are unlikely to resolve quickly, making it a high-risk investment.

Financial Highlights

debt To Equity

N/A

revenue

$388,545

operating Margin

N/A

total Assets

$1,764,557

total Debt

$7,197,972

net Income

-$851,800

eps

N/A

gross Margin

N/A

cash Position

$10,911

revenue Growth

-34.1%

Revenue Breakdown

Key Numbers

• $10,911 — Cash at September 30, 2025 (Represents a significant decrease from $76,241 at December 31, 2024, indicating severe liquidity issues.)
• $851,800 — Net loss for Q3 2025 (Improved from $1,973,119 in Q3 2024, but still a substantial loss.)
• $2,603,777 — Net loss for the nine months ended September 30, 2025 (Improved from $4,901,273 in the prior year, but still a significant deficit.)
• $388,545 — Total revenue for Q3 2025 (Decreased from $590,124 in Q3 2024, indicating declining sales.)
• $1,755,113 — Total revenue for the nine months ended September 30, 2025 (Decreased from $2,389,434 in the prior year, showing a consistent revenue decline.)
• $7,197,972 — Total Liabilities at September 30, 2025 (Increased from $5,352,198 at December 31, 2024, driven by related party debt.)
• $5,216,072 — Notes payable to related party at September 30, 2025 (Increased significantly from $3,212,521 at December 31, 2024, indicating reliance on related party financing.)
• 1-for-100 — Reverse Stock Split Ratio (Effected on September 4, 2025, reducing outstanding shares from 284,750,832 to 2,847,873.)

Key Players & Entities

• HealthLynked Corp. (company) — Registrant and parent company
• Naples Center for Functional Medicine (company) — Health Services Division subsidiary
• Bridging the Gap Physical Therapy (company) — Health Services Division subsidiary, sold in October 2025
• Concierge Care Naples (company) — Health Services Division subsidiary
• Aesthetic Enhancements Unlimited (company) — Health Services Division subsidiary
• MedOffice Direct LLC (company) — Medical Distribution Division subsidiary
• SEC (regulator) — Securities and Exchange Commission
• Nevada (company) — State of incorporation for HealthLynked Corp.

FAQ

Risk Factors

• Severe Liquidity Constraints [high — financial]: The company's cash position has drastically deteriorated, falling from $76,241 at December 31, 2024, to just $10,911 at September 30, 2025. This severe lack of liquidity poses an immediate threat to ongoing operations and the ability to meet short-term obligations.
• Increasing Indebtedness [high — financial]: Total liabilities have surged from $5,352,198 to $7,197,972, primarily driven by a significant increase in notes payable to related parties, which rose from $3,212,521 to $5,216,072. This reliance on related party financing indicates potential financial distress and dependence.
• Declining Revenue Trend [medium — financial]: Total revenue for Q3 2025 was $388,545, a decrease from $590,124 in Q3 2024. The nine-month revenue also declined to $1,755,113 from $2,389,434. This consistent downward trend in revenue, particularly in patient services, raises concerns about the company's ability to generate sustainable income.
• Reduced Operating Expenses Masking Underlying Issues [medium — operational]: While operating expenses decreased substantially from $2,261,471 to $918,131 in Q3 2025, this was partly due to the absence of a $716,000 impairment loss recorded in 2024. The reduction in practice salaries and benefits may impact operational capacity.
• Negative Shareholders' Deficit [high — financial]: The company has a substantial and growing shareholders' deficit, increasing from ($3,129,209) at December 31, 2024, to ($5,433,415) at September 30, 2025. This indicates that liabilities exceed assets, a sign of financial insolvency.
• Impact of Reverse Stock Split [low — financial]: A 1-for-100 reverse stock split was executed on September 4, 2025. While intended to increase the per-share price, it does not address the underlying financial challenges and may signal desperation to meet listing requirements.

Industry Context

The healthcare technology sector is highly competitive, with companies vying for market share through innovation and efficient service delivery. Trends include increasing adoption of digital health platforms, telehealth services, and data analytics for patient care improvement. However, regulatory hurdles, data privacy concerns, and the need for significant capital investment are persistent challenges.

Regulatory Implications

Companies in the healthcare sector are subject to stringent regulations regarding patient data privacy (e.g., HIPAA in the US) and service provision. Non-compliance can lead to significant fines and reputational damage. HealthLynked Corp.'s financial instability could also attract scrutiny regarding its ability to meet ongoing regulatory obligations.

What Investors Should Do

1. Monitor cash burn rate closely.
2. Analyze the sustainability of related party financing.
3. Evaluate the drivers of revenue decline.
4. Assess the impact of the reverse stock split.

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the latest financial results, showing a reduced net loss but declining revenue and severely depleted cash reserves.
• 2025-09-04: 1-for-100 Reverse Stock Split — Reduced the number of outstanding shares from 284,750,832 to 2,847,873, a move often made to artificially boost share price.
• 2025-09-30: Cash Balance Reported — Stood at $10,911, highlighting critical liquidity issues.
• 2025-09-30: Total Liabilities Reported — Reached $7,197,972, an increase driven by related party debt.

Glossary

Shareholders' Deficit

A negative value for shareholders' equity, meaning the company's liabilities exceed its assets. (HealthLynked Corp. has a significant and growing shareholders' deficit, indicating a precarious financial position.)

Notes payable to related party

Money owed by the company to individuals or entities that have a close relationship with the company, such as major shareholders or management. (This category of debt has increased substantially, showing the company's reliance on financing from insiders.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating them. (HealthLynked Corp. executed a 1-for-100 reverse split, significantly reducing share count, often to meet stock exchange listing requirements or improve share price perception.)

Accumulated deficit

The cumulative net losses of a company since its inception, minus any net profits. (HealthLynked Corp.'s accumulated deficit has widened, reflecting ongoing operational losses.)

Year-Over-Year Comparison

Compared to the prior year, HealthLynked Corp. has significantly reduced its net loss for both the three-month period (from $1,973,119 to $851,800) and the nine-month period (from $4,901,273 to $2,603,777). However, this improvement comes alongside a substantial decline in total revenue, which fell from $590,124 to $388,545 in the third quarter and from $2,389,434 to $1,755,113 for the nine months. Operating expenses were also reduced, but the company's cash position has critically worsened, and total liabilities have increased, primarily due to related party debt.

Key Financial Figures

• $0 — of the issuer's common stock, par value $0.0001, outstanding. TABLE OF CONTENTS

Filing Documents

• ea0265928-10q_health.htm (10-Q) — 1792KB
• ea026592801ex3-1_health.htm (EX-3.1) — 6KB
• ea026592801ex31-1_health.htm (EX-31.1) — 16KB
• ea026592801ex31-2_health.htm (EX-31.2) — 16KB
• ea026592801ex32-1_health.htm (EX-32.1) — 6KB
• ea026592801ex32-2_health.htm (EX-32.2) — 6KB
• ex3-1_001.jpg (GRAPHIC) — 513KB
• ex3-1_002.jpg (GRAPHIC) — 374KB
• 0001213900-25-112578.txt ( ) — 11878KB
• hlyk-20250930.xsd (EX-101.SCH) — 112KB
• hlyk-20250930_cal.xml (EX-101.CAL) — 51KB
• hlyk-20250930_def.xml (EX-101.DEF) — 438KB
• hlyk-20250930_lab.xml (EX-101.LAB) — 806KB
• hlyk-20250930_pre.xml (EX-101.PRE) — 465KB
• ea0265928-10q_health_htm.xml (XML) — 1955KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 39 Item 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 46 Item 4

Controls and Procedures

Controls and Procedures 46 Part II OTHER INFORMATION 47 Item 1

Legal Proceedings

Legal Proceedings 47 Item 1A

Risk Factors

Risk Factors 47 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 3 Defaults upon Senior Securities 48 Item 4 Mine Safety Disclosure 48 Item 5 Other Information 48 Item 6 Exhibits 48 i

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements HEALTHLYNKED CORP. CONDENSED CONSOLIDATED BALANCE SHEETS September 30 December 31, 2025 2024 ASSETS (Unaudited) Current Assets Cash $ 10,911 $ 76,241 Inventory, net 31,977 44,686 Prepaid expenses and other current assets 36,559 56,719 Contingent sale consideration receivable, current portion 1,463,518 1,463,518 Total Current Assets 1,542,965 1,641,164 Property and equipment, net of accumulated depreciation of $ 702,256 and $ 634,839 as of September 30, 2025 and December 31, 2024, respectively 101,159 176,576 Right of use lease assets 120,433 361,109 Deposits, long term portion — 44,140 Total Assets $ 1,764,557 $ 2,222,989 LIABILITIES AND SHAREHOLDERS' DEFICIT Current Liabilities Accounts payable, accrued expenses and other current liabilities $ 785,982 $ 765,312 Contract liabilities 47,735 232,545 Lease liability, current portion 116,762 208,549 Derivative financial instruments 75,732 — Notes payable and other amounts due to related party, net of unamortized original issue discount of $ 32,739 and $ 494,104 as of September 30, 2025 and December 31, 2024, respectively 5,216,072 3,212,521 Notes payable, current portion, net of unamortized original issue discount of $ 92,294 and $ 27,414 as of September 30, 2025 and December 31, 2024, respectively 293,937 127,095 Indemnification liability 143,974 143,974 Current liabilities held for sale 64,107 — Total Current Liabilities 6,744,301 4,689,996 Long-Term Liabilities Lease liability, long term portion 3,671 153,592 Government and other notes payable, long term portion 450,000 508,610 Total Liabilities 7,197,972 5,352,198 Commitments and contingencies (Note 15) Shareholders' Deficit Common stock, par value $ 0.0001 per share, 500,000,000 shares authorized, 2,847,873 and 2,821,877 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 285 282 Series

View Full Filing

View this 10-Q filing on SEC EDGAR